132 related articles for article (PubMed ID: 9731839)
1. Expression of gamma-glutamyl transpeptidase in stage III and IV ovarian surface epithelial carcinomas does not alter response to primary cisplatin-based chemotherapy.
Hanigan MH; Frierson HF; Taylor PT
Am J Obstet Gynecol; 1998 Aug; 179(2):363-7. PubMed ID: 9731839
[TBL] [Abstract][Full Text] [Related]
2. Human germ cell tumours: expression of gamma-glutamyl transpeptidase and sensitivity to cisplatin.
Hanigan MH; Frierson HF; Abeler VM; Kaern J; Taylor PT
Br J Cancer; 1999 Sep; 81(1):75-9. PubMed ID: 10487615
[TBL] [Abstract][Full Text] [Related]
3. Human ovarian tumors express gamma-glutamyl transpeptidase.
Hanigan MH; Frierson HF; Brown JE; Lovell MA; Taylor PT
Cancer Res; 1994 Jan; 54(1):286-90. PubMed ID: 7903206
[TBL] [Abstract][Full Text] [Related]
4. [A case of poorly differentiated ovarian serous adenocarcinoma responding favorably to etoposide and cisplatin].
Sato Y; Nishida M; Inoue K; Arai Y; Sasaki J; Kubo T
Gan To Kagaku Ryoho; 1996 Nov; 23(13):1847-9. PubMed ID: 8937497
[TBL] [Abstract][Full Text] [Related]
5. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study.
Bloss JD; Brady MF; Liao SY; Rocereto T; Partridge EE; Clarke-Pearson DL;
Gynecol Oncol; 2003 Apr; 89(1):148-54. PubMed ID: 12694669
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma].
Gao YN; Liu JX; Wang W; Li WF; Tang WS
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):171-3. PubMed ID: 15946570
[TBL] [Abstract][Full Text] [Related]
7. Gamma-glutamyl transpeptidase accelerates tumor growth and increases the resistance of tumors to cisplatin in vivo.
Hanigan MH; Gallagher BC; Townsend DM; Gabarra V
Carcinogenesis; 1999 Apr; 20(4):553-9. PubMed ID: 10223181
[TBL] [Abstract][Full Text] [Related]
8. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
11. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Dubernard G; Morice P; Rey A; Camatte S; Fourchotte V; Thoury A; Pomel C; Pautier P; Lhommé C; Duvillard P; Castaigne D
Eur J Surg Oncol; 2004 Nov; 30(9):976-81. PubMed ID: 15498644
[TBL] [Abstract][Full Text] [Related]
12. [Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
Yan X; An N; Jiang GQ; Gao M; Gao YN
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):298-301. PubMed ID: 18788637
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin nephrotoxicity: inhibition of gamma-glutamyl transpeptidase blocks the nephrotoxicity of cisplatin without reducing platinum concentrations in the kidney.
Hanigan MH; Gallagher BC; Taylor PT
Am J Obstet Gynecol; 1996 Aug; 175(2):270-3; discussion 273-4. PubMed ID: 8765241
[TBL] [Abstract][Full Text] [Related]
14. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
16. Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line.
el-akawi Z; Zdanowicz J; Creaven PJ; Abu-hadid M; Perez R; Pendyala L
Oncol Res; 1996; 8(10-11):415-23. PubMed ID: 9114434
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
Goldberg JM; Piver MS; Hempling RE; Recio FO
Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
[TBL] [Abstract][Full Text] [Related]
18. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
19. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome.
Surowiak P; Materna V; Kaplenko I; Spaczynski M; Dolinska-Krajewska B; Gebarowska E; Dietel M; Zabel M; Lage H
Clin Cancer Res; 2006 Dec; 12(23):7149-58. PubMed ID: 17145840
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
